Journal article

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

Fiona M Blows, Kristy E Driver, Marjanka K Schmidt, Annegien Broeks, Flora E van Leeuwen, Jelle Wesseling, Maggie C Cheang, Karen Gelmon, Torsten O Nielsen, Carl Blomqvist, Paivi Heikkila, Tuomas Heikkinen, Heli Nevanlinna, Lars A Akslen, Louis R Begin, William D Foulkes, Fergus J Couch, Xianshu Wang, Vicky Cafourek, Janet E Olson Show all



BACKGROUND: Immunohistochemical markers are often used to classify breast cancer into subtypes that are biologically distinct and behave differently. The aim of this study was to estimate mortality for patients with the major subtypes of breast cancer as classified using five immunohistochemical markers, to investigate patterns of mortality over time, and to test for heterogeneity by subtype. METHODS AND FINDINGS: We pooled data from more than 10,000 cases of invasive breast cancer from 12 studies that had collected information on hormone receptor status, human epidermal growth factor receptor-2 (HER2) status, and at least one basal marker (cytokeratin [CK]5/6 or epidermal growth factor rece..

View full abstract


Awarded by Dutch Cancer Society

Awarded by Helsinki University Central Hospital Research Fund, Academy of Finland

Awarded by US National Institutes of Health

Awarded by NIH

Awarded by Australian NHMRC


Awarded by Cancer Research UK

Awarded by The Francis Crick Institute

Funding Acknowledgements

Funding: Funding of the Amsterdam Breast Cancer Study was provided by the Dutch Cancer Society (grants NKI 2001-2423; 2007-3839) and the Dutch National Genomics Initiative. The Helsinki Breast Cancer Study has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (110663), the Finnish Cancer Society, and the Sigrid Juselius Foundation. The immunohistochemical analysis of cases from the Jewish General Hospital and Vancouver General Hospital studies was funded by the Canadian Breast Cancer Research Alliance. The Mayo Clinic Breast Cancer Study study was funded by US National Institutes of Health grant CA122340 and an NIH Sponsored Program of Research Excellence (SPORE) in Breast Cancer (CA116201). The immunohistochemical analysis of breast cancers from the Melbourne Collaborative Cohort Study was supported by Australian NHMRC grants 209057, 251553 and 504711 and infrastructure provided by The Cancer Council Victoria. Polish Breast Cancer Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Sheffield Breast Cancer Study was supported by Yorkshire Cancer Research and the Breast Cancer Campaign. The Study of Epidemiology and Risk factors in Cancer Heredity is funded by a programme grant from Cancer Research UK. The UK NIHR Cambridge Biomedical Research Centre and the Cambridge Experimental Cancer Medicine Centre support the work of EP, S-JD, CC, and PDP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.